A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Recruiting · Phase 2 · NCT06588478
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
At a glance
- Research payments reported, 2025
- $742,849
- U.S. investigators named
- 20
- Sites paid
- 18
- Planned or actual enrollment
- 249
About the trial
- Sponsor
- Loxo Oncology, Inc. (with Eli Lilly and Company)
- Tested
- Pirtobrutinib (drug)
- Dates
- Started 2025-01-03; completion 2028-12
- Results posted
- Not yet
The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of treatment including a covalent Bruton tyrosine kinase (BTK) inhibitor. The purpose of Part 2 of this study is to evaluate pirtobrutinib monotherapy in participants with treatment-naïve CLL/SLL with 17p deletions. Participation in Part 1 is expected to last approximately 3 years. Participation in Part 2 is expected to last up to 2 years.
From ClinicalTrials.gov, last updated 2026-11-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $742,849 in research payments for this study in 2025 (35 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Michael A. Musci, MD Hematology & Oncology · Mesa, AZ
- Alexey Danilov, M.D. Hematology · Duarte, CA
- Roozbeh Mohajer, MD Hematology & Oncology · Palo Alto, CA
- John M. Burke, MD Hematology & Oncology · Aurora, CO
- Alvaro J. Alencar, M.D. Hematology & Oncology · Miami, FL
- Sabarish R. Ayyappan, MD Hematology · Iowa City, IA
- Tara M. Graff, DO Medical Oncology · Clive, IA
- Miguel A. Islas-ohlmayer, MD Hematology & Oncology · Edgewood, KY
- Andrew B. Wilks, M.D. Hematology · Boston, MA
- Bruce D. Cheson, MD Hematology · Bethesda, MD
- Victor M. Priego, M.D. Medical Oncology · Bethesda, MD
- Pamela Tuli, MD Hematology & Oncology · Gulfport, MS
- Darla K. Liles, MD Hematology & Oncology · Greenville, NC
- Anthony V. Nguyen, MD Hematology & Oncology · Henderson, NV
- James D'olimpio Hematology & Oncology · Lake Success, NY
- Jackson Y. Gao, MD Hematology & Oncology · York, PA
- Jason C. Chandler, M.D Medical Oncology · Germantown, TN
- Jason M. Melear, M.D. Medical Oncology · Austin, TX
- Celesteann Bremer, M.D. Hematology & Oncology · Virginia Beach, VA
- Tristan C. Bice, MD Hematology & Oncology · Vancouver, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- City of Hope National Medical Ctr $305,390
- Cancer Care Associates of York, Inc $99,738
- Ironwood Cancer and Research Centers $86,033
- Comprehensive Cancer Centers of Nevada $75,054
- St Elizabeth Edgewood, KY $58,459
- Boston Medical Center, MA $26,149
- The West Clinic $25,382
- University of Miami $19,519
- Palo Alto Medical Foundation $19,410
- Mission Cancer and Blood PLLC $15,400
- Memorial Hospital at Gulfport, MS $4,000
- $3,291
- US Oncology Research LLC $1,825
- East Carolina University $1,393
- Northwest Cancer Specialists PC $609
- Qcca Network, LLC $476
- American Oncology PArtners of Maryland PA $409
- Gulfport Memorial Hosp $173
- Clinical Research Alliance Inc $138
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.